ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) had its Buy rating reiterated by JPMorgan Chase & Co.

Analyst Ratings For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Story continues below

Today, JPMorgan Chase & Co. reiterated its Buy rating on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD).

There are 8 Buy Ratings, 3 Hold Ratings, 1 Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is Buy with a consensus target price of $43.8333 per share, a potential 12.83% upside.

Some recent analyst ratings include

  • 9/10/2019-ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) had its Buy rating reiterated by JPMorgan Chase & Co.
  • 9/10/2019-ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) gets upgraded to Buy by Canaccord Genuity with a price target of $50.00
  • 9/9/2019-ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) had its Buy rating reiterated by Cowen with a $66.00 price target
  • 8/27/2019-ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) had its Overweight rating reiterated by Cantor Fitzgerald with a $40.00 price target
  • On 1/9/2019 Laura Brege, Director, sold 10,000 with an average share price of $20.00 per share and the total transaction amounting to $200,000.00.
  • On 11/30/2018 Bros. Advisors Lp Baker, Director, bought 11,764,705 with an average share price of $17.00 per share and the total transaction amounting to $199,999,985.00.
  • On 9/20/2018 Bros. Advisors Lp Baker, Director, bought 1,210,776 with an average share price of $18.70 per share and the total transaction amounting to $22,641,511.20.
  • On 3/1/2018 Daniel B Soland, Director, bought 7,000 with an average share price of $23.91 per share and the total transaction amounting to $167,370.00.
  • On 1/29/2018 Glenn Baity, EVP, sold 36,558 with an average share price of $32.39 per share and the total transaction amounting to $1,184,113.62.
  • On 1/2/2018 Glenn Baity, EVP, sold 74,321 with an average share price of $30.14 per share and the total transaction amounting to $2,240,034.94.
  • On 1/2/2018 Laura Brege, Director, sold 25,000 with an average share price of $30.06 per share and the total transaction amounting to $751,500.00.

Recent Trading Activity for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Shares of ACADIA Pharmaceuticals Inc. closed the previous trading session at 38.85 up +15.05 63.24% with 41.75 shares trading hands.

An ad to help with our costs